Hormone therapy in perimenopause linked to lower cardiovascular risk in new 2026 study

One of the most contested questions in women’s health is whether hormone therapy helps or harms the heart. A study led by Virginia Commonwealth University and the University of Pittsburgh, published in JAMA Internal Medicine on September 9, 2026, adds important evidence: among women with hot flashes and night sweats who started menopausal hormone therapy during perimenopause or shortly after their final period, cardiovascular disease risk was lower than among comparable women who did not start.

What the researchers did

Using a target-trial emulation design — an approach that structures observational data to mimic a randomized trial — investigators compared women with vasomotor symptoms who initiated hormone therapy in perimenopause or recent postmenopause with those who did not, then followed cardiovascular events over time. It is described as the first U.S. study of its kind to focus specifically on the cardiovascular impact of hormone therapy started during perimenopause rather than years later.

Why the timing matters so much

This is the timing hypothesis, and it is the single most important idea for understanding the last twenty years of confusion. The 2002 Women’s Health Initiative results that frightened a generation came from women whose average age was 63 — more than a decade past menopause, when arterial plaque is already established. Starting estrogen in that setting behaves differently than starting it while blood vessels are still relatively healthy. The new analysis supports the view that initiating therapy close to the transition is not merely safer, but may be cardioprotective in symptomatic women.

Important limits

• This is observational research, not a randomized trial. Residual confounding is possible — women who start hormone therapy may be healthier in ways the data cannot fully capture.
• The benefit was observed in women with vasomotor symptoms, who may represent a distinct biological group.
• It does not establish hormone therapy as a heart disease prevention drug, and no major guideline currently recommends it for that purpose.
• It does not change contraindications: prior breast cancer, unexplained bleeding, active liver disease, or recent clot, stroke, or heart attack.

Route and formulation still matter

Modern regimens differ substantially from the WHI protocols. Transdermal estradiol — a patch, gel, or spray — bypasses first-pass liver metabolism and is associated with lower clotting risk than oral estrogen, particularly in women with elevated baseline risk. Micronized progesterone is used for endometrial protection in women with a uterus. These distinctions are why a blanket statement about “HRT and the heart” is close to meaningless without specifying who, when, what, and how.

Context: demand is rising fast

The clinical news arrives during a documented surge in demand. Prescriptions for estrogen patches have risen sharply, and supply of some patch products has been tight through 2026 — a practical reason to discuss alternatives, dosing, and pharmacy options with your prescriber rather than assuming your usual product will always be on the shelf.

What this means for you

• If you have bothersome hot flashes or night sweats and you are under 60 or within ten years of your final period, hormone therapy is worth a real conversation — not a reflexive no.
• Get your cardiovascular baseline before starting: blood pressure, lipids including apoB, A1c, weight trend, and personal and family history.
• Ask specifically about transdermal estradiol if you have clotting, migraine with aura, or metabolic risk considerations.
• Do not start hormone therapy solely to prevent heart disease. Start it for symptoms, bone protection, or early menopause — and treat cardiovascular risk with the tools proven for that job.
• Keep treating the fundamentals: blood pressure control, strength training, sleep, and smoking cessation outperform any hormone decision for heart outcomes.

The bottom line

The evidence continues to move away from the blanket fear of the early 2000s and toward a more precise question: for this woman, with these symptoms, at this point in her transition, with this history, is hormone therapy the right tool? For many symptomatic women in perimenopause and early postmenopause, this study suggests the cardiovascular ledger looks better than they were told.

This article is education, not a substitute for individual medical advice. Hormone therapy is a prescription decision that requires review of your full medical history by a licensed clinician.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: September 10, 2026